🧬 AOD‑9604 – Research Overview
0. Category:
Metabolic Health, Weight Loss, Fat Loss, Metabolic Efficiency
1. Primary Research Use:
AOD‑9604 is a synthetic fragment derived from human growth hormone (hGH) (specifically residues 177–191), researched for targeted fat loss by boosting lipolysis and limiting lipogenesis—without the broad hormonal effects typical of full-length hGH.
2. Simple Analogy:
Think of AOD‑9604 as a precision fat-burning key—unlocking your body’s ability to burn stubborn fat specifically, while bypassing the broader “growth hormone highways” that lead to systemic effects.
3. What It Is (Chemical Summary):
AOD‑9604 is a 16‑amino‑acid peptide fragment of the hGH C‑terminus, with a stabilizing tyrosine residue at the N-terminus. It’s designed to stimulate fat metabolism via beta‑3 adrenergic receptors, without engaging IGF‑1 pathways.
4. Best Suited For:
Ideal for research involving abdominal fat reduction, metabolic syndrome, or metabolic health in individuals who want fat loss without altering blood sugar or IGF‑1 levels. It’s particularly suitable for those seeking targeted fat–focused results without broad systemic changes.
5. Not Recommended For / Caution In Research With:
Use caution in individuals with pregnancy or breastfeeding (limited safety data), as well as those with growth‑related cancers (due to derivative of hGH). Also monitor those with diabetes or metabolic instability, despite generally minimal insulin impact.
6. Synergistic Peptide Stacks:
-
GLP‑1 agonists (e.g., Tirzepatide): Add appetite suppression to AOD‑9604’s fat‑burning.
-
CJC‑1295 + Ipamorelin: Support muscle retention alongside fat loss.
-
BPC‑157 or TB‑500: Aid tissue repair during body composition shifts.
7. Common Dosing Guidelines (Research Use):
| Experience Level | Daily Dosage |
|---|---|
| Beginner | 300 µg oral or SC† |
| Intermediate | 500 µg daily |
| Advanced | Up to 1 mg daily‡ |
†Typical morning administration on an empty stomach is common.
‡Human trials tested daily doses between 0.25–1 mg safely, with good tolerability.
8. Cycling Information:
Studies have used continuous daily administration for 12 to 24 weeks. Though some earlier trials showed modest weight effects, longer-term fat loss outcomes were mixed.
9. Similar Peptides & Comparison Chart:
| Compound | Mechanism of Action | Dosing Frequency | Notes |
|---|---|---|---|
| AOD-9604 | hGH fragment—lipolytic, fat‑targeted | Daily | Focused fat loss, minimal IGF‑1 impact |
| Tesamorelin | GHRH analog | Daily | Abdominal fat loss, GH-release |
| Tirzepatide | GLP‑1 receptor agonist | Weekly | Appetite suppression + fat loss |
| Cagrilintide | Amylin analogue | Weekly | Satiety + weight regulation |
10. Method of Administration:
Administered via subcutaneous injection or oral lozenge/formulation, typically once daily—often in the morning on an empty stomach.
11. Regulatory Status (FDA Approval):
AOD‑9604 is not FDA‑approved and remains investigational. Development was discontinued in 2007 after later trials failed to confirm strong efficacy.
12. Legal Disclaimer:
All products discussed are intended for laboratory, scientific, and research purposes only. AOD-9604 is not FDA-approved for human or veterinary use and is not intended to diagnose, treat, cure, or prevent any disease. Use is strictly investigational.
Information provided is for educational purposes only, not medical advice. Consult a licensed healthcare professional before starting or designing any peptide research protocols. By accessing this content, you affirm you are a qualified researcher or under appropriate supervision. All sales are final.
Reviews
There are no reviews yet.